{"denoms":[{"counts":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"197"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous rituximab (Rituxan, Genentech) (at a dose of 375 mg per square meter of body-surface area once weekly for 4 weeks) plus daily placebo-cyclophosphamide. Refer to section titled \"Detailed Description\" for additional treatment information.","id":"BG000","title":"Rituximab"},{"description":"Participants received placebo-rituximab infusions plus daily cyclophosphamide (2 mg per kilogram of body weight, adjusted for renal insufficiency). Refer to section titled \"Detailed Description\" for additional treatment information.","id":"BG001","title":"Control Group"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"136"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"55"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"16.8","value":"54.0"},{"groupId":"BG001","spread":"14.1","value":"51.5"},{"groupId":"BG002","spread":"15.5","value":"52.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"97"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"100"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"181"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}]}],"title":"Netherlands"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.8","value":"8.1"},{"groupId":"BG001","spread":"3.4","value":"8.0"},{"groupId":"BG002","spread":"3.1","value":"8.0"}]}]}],"description":"The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (WG) is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease. In this study, the primary end point was a BVAS/WG score of 0 and successful completion of the prednisone taper at 6 months.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"BVAS/WG","unitOfMeasure":"score units"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.8","value":"1.4"},{"groupId":"BG001","spread":"1.4","value":"1.0"},{"groupId":"BG002","spread":"1.7","value":"1.2"}]}]}],"description":"Vasculitis Damage Index. The VDI is a validated measure for damage assessment in vasculitis. The index comprises 64 items of damage (divided into 11 organ based systems) representative of damage incurred to patients with systemic vasculitis. Scores for this index range from 0 to 64, with higher scores indicating more severe damage.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"VDI","unitOfMeasure":"score units"}]}